Therefore, a deeper understanding of the role of CD38 on early transcriptomic and metabolic changes of M‐MDSCs is essential for pharmacological and/or non‐pharmacological interventions for age‐related bone loss and fracture risk. This evidence concerns the gene CD38 and age.